免疫检查点抑制剂肾毒性:已知与应对
本文综述免疫检查点抑制剂相关肾毒性的表现与处理。此类药物不依赖肝肾排泄、半衰期长,可致急性肾损伤和/或蛋白尿;肾活检最常见为急性小管间质性肾炎。临床和实验室指标难以预测病变,多数需肾活检确诊;推荐停药并糖皮质激素治疗,再暴露风险不一,肾移植患者需警惕急性排斥。
要点
- 免疫检查点抑制剂可致急性肾损伤和/或蛋白尿,最常见为急性小管间质性肾炎。
- 临床和实验室指标难以预测肾脏病变,多数需肾活检确诊并指导治疗。
- 急性小管间质性肾炎推荐停药并糖皮质激素治疗,再暴露需密切监测。
核心结论
- 免疫检查点抑制剂相关肾损伤以急性小管间质性肾炎最常见,诊断常需肾活检,治疗以停药和糖皮质激素为主。
研究设计与样本
- 综述,总结免疫检查点抑制剂肾毒性的临床表现、病理类型、诊断与治疗。
主要发现
- 肾活检最常见为急性小管间质性肾炎,急性肾小管损伤和肾小球病变较少见。
- 临床和实验室检查难以预测 underlying 肾脏病变,多数病例需肾活检确诊。
- 既往发生急性小管间质性肾炎者再暴露后结局不一,需密切监测急性肾损伤复发。
- 肾移植患者使用免疫检查点抑制剂有发生急性排斥的风险,需密切监测。
关键数值与推荐
- 急性小管间质性肾炎推荐停用免疫检查点抑制剂并给予糖皮质激素治疗。
- 再暴露是否合适尚不明确,在治疗选择有限的患者中可考虑,但需密切监测急性肾损伤复发。
临床怎么用
- 对使用免疫检查点抑制剂并出现急性肾损伤和/或蛋白尿者,应评估肾毒性并考虑肾活检。
- 确诊急性小管间质性肾炎后,应停用免疫检查点抑制剂并给予糖皮质激素。
- 对既往发生急性小管间质性肾炎者再暴露需谨慎并密切监测肾功能。
- 肾移植患者使用时需密切监测急性排斥。
局限性
- 再暴露经验基于少量病例,是否合适尚不明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Immune checkpoint inhibitors have dramatically improved cancer therapy for many patients. These humanized monoclonal antibodies against various immune checkpoints (receptors and ligands) effectively treat a number of malignancies by unleashing the immune system to destroy cancer cells. These drugs are not excreted by the kidneys or liver, have a long half-life, and undergo receptor-mediated clearance. Although these agents have greatly improved the prognosis of many cancers, immune-related end organ injury is a complication that has come to light in clinical practice. Although less common than other organ involvement, kidney lesions resulting in acute kidney injury and/or proteinuria are being described. Acute tubulointerstitial nephritis is the most common lesion seen on kidney biopsy, while acute tubular injury and glomerular lesions occur less commonly. Clinical findings and laboratory tests are suboptimal in predicting the underlying renal lesion, making kidney biopsy necessary in the majority of cases to definitely diagnose the lesion and potentially guide therapy. Immune checkpoint inhibitor discontinuation and corticosteroid therapy are recommended for acute tubulointerstitial nephritis. Based on a handful of cases, re-exposure to these drugs in patients who previously developed acute tubulointerstitial nephritis has been mixed. Although it is unclear whether re-exposure is appropriate, it should perhaps be considered in patients with limited options. When this approach is taken, patients should be closely monitored for recurrence of acute kidney injury. Treatment of cancer in patients with a kidney transplant with immune checkpoint inhibitors risks the development of acute rejection in some patients and requires close surveillance.
引用
- Perazella MA, Shirali AC. Immune checkpoint inhibitor nephrotoxicity: what do we know and what should we do? Kidney Int. 2019. PMID: 31685311. doi:10.1016/j.kint.2019.07.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。